{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T07:53:24Z","timestamp":1780473204951,"version":"3.54.1"},"reference-count":224,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2016,6,1]],"date-time":"2016-06-01T00:00:00Z","timestamp":1464739200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","theclinics.com","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Psychiatric Clinics of North America"],"published-print":{"date-parts":[[2016,6]]},"DOI":"10.1016\/j.psc.2016.01.008","type":"journal-article","created":{"date-parts":[[2016,3,29]],"date-time":"2016-03-29T04:05:10Z","timestamp":1459224310000},"page":"275-311","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":29,"title":["Detecting and Managing Adverse Effects of Antipsychotic Medications"],"prefix":"10.1016","volume":"39","author":[{"given":"Donna","family":"Ames","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sian M.","family":"Carr-Lopez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mary A.","family":"Gutierrez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph M.","family":"Pierre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer A.","family":"Rosen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susan","family":"Shakib","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lynn M.","family":"Yudofsky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.psc.2016.01.008_bib1","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/S0193-953X(02)00035-7","article-title":"Understanding the new and evolving profile of adverse drug effects in schizophrenia","volume":"26","author":"Wirshing","year":"2003","journal-title":"Psychiatr Clin North Am"},{"key":"10.1016\/j.psc.2016.01.008_bib2","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1002\/j.2051-5545.2011.tb00014.x","article-title":"Physical illness in patients with severe mental disorders. I. Prevalence, impact of medications and disparities in health care","volume":"1","author":"De Hert","year":"2011","journal-title":"World Psychiatry"},{"key":"10.1016\/j.psc.2016.01.008_bib3","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/j.jad.2007.12.233","article-title":"Prevalence and correlates of overweight in drug-na\u00efve patients with bipolar disorder","volume":"1-2","author":"Maina","year":"2008","journal-title":"J\u00a0affective Disord"},{"key":"10.1016\/j.psc.2016.01.008_bib4","first-page":"A42","article-title":"Congruencies in increased mortality rates, years of potential life lost, and causes of death among public mental health clients in eight states","volume":"2","author":"Colton","year":"2006","journal-title":"Preventing Chronic Dis"},{"key":"10.1016\/j.psc.2016.01.008_bib5","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1097\/JCP.0b013e318172b8e6","article-title":"Effect of antipsychotics on peptides involved in energy balance in drug-naive psychotic patients after 1 year of treatment","volume":"3","author":"Perez-Iglesias","year":"2008","journal-title":"J\u00a0Clin Psychopharmacol"},{"issue":"6","key":"10.1016\/j.psc.2016.01.008_bib6","doi-asserted-by":"crossref","first-page":"358","DOI":"10.4088\/JCP.v60n0602","article-title":"Novel Antipsychotics: Comparison of Weight Gain Liabilities","volume":"60","author":"Wirshing","year":"1999","journal-title":"J\u00a0Clin Psychiatry"},{"key":"10.1016\/j.psc.2016.01.008_bib7","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1111\/j.1600-0447.2008.01334.x","article-title":"Which comes first: atypical antipsychotic treatment or cardiometabolic risk?","volume":"3","author":"Stahl","year":"2009","journal-title":"Acta Psychiatr Scand"},{"key":"10.1016\/j.psc.2016.01.008_bib8","first-page":"1","article-title":"The role of histaminergic H1 and H3 receptors in food intake: a mechanism for atypical antipsychotic-induced weight gain?","volume":"1","author":"Deng","year":"2009","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"issue":"3","key":"10.1016\/j.psc.2016.01.008_bib9","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1038\/mp.2011.109","article-title":"Pharmacogenetics of antipsychotic-induced weight gain: review and clinical implications","volume":"17","author":"Lett","year":"2012","journal-title":"Mol Psychiatry"},{"key":"10.1016\/j.psc.2016.01.008_bib10","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1097\/chi.0b013e31815b5cb1","article-title":"Antipsychotic use in children and adolescents: minimizing adverse effects to maximize outcomes","volume":"1","author":"Correll","year":"2008","journal-title":"J\u00a0Am Acad Child Adolesc Psychiatry"},{"key":"10.1016\/j.psc.2016.01.008_bib11","first-page":"146","article-title":"The effects of second-generation antipsychotics on food intake, resting energy expenditure and physical activity","volume":"2","author":"Cuerda","year":"2013","journal-title":"Eur J Clin Nutr"},{"key":"10.1016\/j.psc.2016.01.008_bib12","doi-asserted-by":"crossref","first-page":"1780","DOI":"10.1038\/oby.2008.277","article-title":"Adiposity and eating behaviors in patients under second generation antipsychotics","volume":"8","author":"Blouin","year":"2008","journal-title":"Obesity"},{"key":"10.1016\/j.psc.2016.01.008_bib13","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1097\/jcp.0b013e31815a8872","article-title":"Clozapine and olanzapine are associated with food craving and binge eating: results from a randomized double-blind study","volume":"6","author":"Kluge","year":"2007","journal-title":"J\u00a0Clin Psychopharmacol"},{"key":"10.1016\/j.psc.2016.01.008_bib14","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1038\/nrendo.2011.156","article-title":"Metabolic and cardiovascular adverse effects associated with antipsychotic drugs","volume":"8","author":"De Hert","year":"2011","journal-title":"Nat Rev Endocrinol"},{"key":"10.1016\/j.psc.2016.01.008_bib15","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1016\/S0140-6736(08)60486-9","article-title":"Effectiveness of antipsychotic drugs in first-episode schizophrenia and schizophreniform disorder: an open randomised clinical trial","volume":"9618","author":"Kahn","year":"2008","journal-title":"Lancet (London, England)"},{"key":"10.1016\/j.psc.2016.01.008_bib16","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1056\/NEJMoa051688","article-title":"Effectiveness of antipsychotic drugs in patients with chronic schizophrenia","volume":"12","author":"Lieberman","year":"2005","journal-title":"N\u00a0Engl J Med"},{"issue":"Suppl 1","key":"10.1016\/j.psc.2016.01.008_bib17","first-page":"1","article-title":"Second-generation (atypical) antipsychotics and metabolic effects: a comprehensive literature review","volume":"19","author":"Newcomer","year":"2005","journal-title":"CNS Drugs"},{"key":"10.1016\/j.psc.2016.01.008_bib18","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.schres.2009.03.025","article-title":"Metabolic profiles of second-generation antipsychotics in early psychosis: findings from the CAFE study","volume":"1-3","author":"Patel","year":"2009","journal-title":"Schizophr Res"},{"issue":"3","key":"10.1016\/j.psc.2016.01.008_bib19","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1016\/j.ecl.2013.05.006","article-title":"Effects of antipsychotic medications on appetite, weight, and insulin resistance","volume":"42","author":"Deng","year":"2013","journal-title":"Endocrinol Metab Clin North Am"},{"key":"10.1016\/j.psc.2016.01.008_bib20","unstructured":"Paliperidone [package insert]. In: Janssen Pharmaceuticals I, editor. Titusville, NJ: 2011."},{"key":"10.1016\/j.psc.2016.01.008_bib21","unstructured":"Lurasidone [package insert]. In: Inc SP, editor. Marlborough, MA: 2013."},{"key":"10.1016\/j.psc.2016.01.008_bib22","unstructured":"Asenapine [package insert]. In: Co M, editor. Whitehouse Station, NJ: 2013."},{"key":"10.1016\/j.psc.2016.01.008_bib23","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1016\/S0140-6736(13)60733-3","article-title":"Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis","volume":"382","author":"Leucht","year":"2013","journal-title":"Lancet"},{"key":"10.1016\/j.psc.2016.01.008_bib24","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1016\/j.ajp.2012.05.005","article-title":"Are there different neural mechanisms responsible for three stages of weight gain development in anti-psychotic therapy: temporally based hypothesis","volume":"4","author":"Pai","year":"2012","journal-title":"Asian J Psychiatr"},{"key":"10.1016\/j.psc.2016.01.008_bib25","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1192\/bjp.187.6.537","article-title":"Course and predictors of weight gain in people with first-episode psychosis treated with olanzapine or haloperidol","volume":"187","author":"Zipursky","year":"2005","journal-title":"Br J Psychiatry"},{"issue":"9","key":"10.1016\/j.psc.2016.01.008_bib26","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.4088\/JCP.v66n0905","article-title":"Clozapine, diabetes mellitus, hperlipidemia, and cardiovascular risks and mortality: results of a 10-year naturalistic study","volume":"66","author":"Henderson","year":"2005","journal-title":"J\u00a0Clin Psychiatry"},{"issue":"4","key":"10.1016\/j.psc.2016.01.008_bib27","doi-asserted-by":"crossref","first-page":"e94112","DOI":"10.1371\/journal.pone.0094112","article-title":"Almost All Antipsychotics Result in Weight Gain: A Meta-Analysis","volume":"9","author":"Bak","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.psc.2016.01.008_bib28","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1097\/01.jcp.0000161501.65890.22","article-title":"Association between early and rapid weight gain and change in weight over one year of olanzapine therapy in patients with schizophrenia and related disorders","volume":"3","author":"Kinon","year":"2005","journal-title":"J\u00a0Clin Psychopharmacol"},{"key":"10.1016\/j.psc.2016.01.008_bib29","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.4088\/JCP.08r04392","article-title":"Are weight gain and metabolic side effects of atypical antipsychotics dose dependent? A literature review","volume":"7","author":"Simon","year":"2009","journal-title":"J\u00a0Clin Psychiatry"},{"key":"10.1016\/j.psc.2016.01.008_bib30","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1097\/01.jcp.0000162800.64378.82","article-title":"The association of weight gain and olanzapine plasma concentrations","volume":"3","author":"Perry","year":"2005","journal-title":"J\u00a0Clin Psychopharmacol"},{"key":"10.1016\/j.psc.2016.01.008_bib31","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1097\/JCP.0b013e3181a289cb","article-title":"Olanzapine plasma concentrations after treatment with 10, 20, and 40\u00a0mg\/d in patients with schizophrenia: an analysis of correlations with efficacy, weight gain, and prolactin concentration","volume":"3","author":"Citrome","year":"2009","journal-title":"J\u00a0Clin Psychopharmacol"},{"key":"10.1016\/j.psc.2016.01.008_bib32","first-page":"181","article-title":"Olanzapine long-acting injection: a 24-week, randomized, double-blind trial of maintenance treatment in patients with schizophrenia","volume":"2","author":"Kane","year":"2009","journal-title":"Am J Psychiatry"},{"key":"10.1016\/j.psc.2016.01.008_bib33","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1111\/j.1600-0447.2006.00899.x","article-title":"Weight development in patients treated with risperidone: a 5-year naturalistic study","volume":"4","author":"Neovius","year":"2007","journal-title":"Acta Psychiatr Scand"},{"key":"10.1016\/j.psc.2016.01.008_bib34","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1111\/j.1600-0447.2008.01158.x","article-title":"Diabetes and schizophrenia - effect of disease or drug? Results from a randomized, double-blind, controlled prospective study in first-episode schizophrenia","volume":"5","author":"Saddichha","year":"2008","journal-title":"Acta Psychiatr Scand"},{"key":"10.1016\/j.psc.2016.01.008_bib35","doi-asserted-by":"crossref","first-page":"92","DOI":"10.4088\/JCP.v62n0204","article-title":"Long-term olanzapine treatment: weight change and weight-related health factors in schizophrenia","volume":"2","author":"Kinon","year":"2001","journal-title":"J\u00a0Clin Psychiatry"},{"key":"10.1016\/j.psc.2016.01.008_bib36","first-page":"620","article-title":"Antipsychotic-induced body weight gain: predictors and a systematic categorization of the long-term weight course","volume":"6","author":"Gebhardt","year":"2008","journal-title":"J\u00a0Psychiatr Res"},{"issue":"1","key":"10.1016\/j.psc.2016.01.008_bib37","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1017\/S1461145713001053","article-title":"Course of weight gain and metabolic abnormalities in first treated episode of psychosis: the first year is a critical period for development of cardiovascular risk factors","volume":"17","author":"Perez-Iglesisas","year":"2014","journal-title":"Int J Neuropsychopharmacol"},{"issue":"2","key":"10.1016\/j.psc.2016.01.008_bib38","doi-asserted-by":"crossref","first-page":"596","DOI":"10.2337\/diacare.27.2.596","article-title":"Consensus development conference on antipsychotic drugs and obesity and diabetes","volume":"27","author":"American Diabetes Association","year":"2004","journal-title":"Diabetes Care"},{"key":"10.1016\/j.psc.2016.01.008_bib39","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.1177\/0269881111430748","article-title":"Comparative effectiveness of switching antipsychotic drug treatment to aripiprazole or ziprasidone for improving metabolic profile and atherogenic dyslipidemia: a 12-month, prospective, open-label study","volume":"9","author":"Chen","year":"2012","journal-title":"J\u00a0Psychopharmacol (Oxford, England)"},{"key":"10.1016\/j.psc.2016.01.008_bib40","series-title":"Diabetes and the metabolic syndrome in mental health","author":"Rosen","year":"2008"},{"issue":"11","key":"10.1016\/j.psc.2016.01.008_bib41","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1176\/ps.2007.58.11.1498","article-title":"Behavioral weight loss classes for patients with severe mental illness","volume":"58","author":"Guzik","year":"2007","journal-title":"Psychiatr Serv"},{"issue":"1","key":"10.1016\/j.psc.2016.01.008_bib42","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1097\/00131746-200601000-00004","article-title":"A\u00a0wellness class for inpatients with psychotic disorders","volume":"12","author":"Wirshing","year":"2006","journal-title":"J\u00a0Psychiatr Pract"},{"issue":"3","key":"10.1016\/j.psc.2016.01.008_bib43","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1016\/j.jand.2013.12.005","article-title":"Nutritional counseling for adults with severe mental illness: key lessons learned","volume":"114","author":"Kwan","year":"2014","journal-title":"J\u00a0Acad Nutr Diet"},{"key":"10.1016\/j.psc.2016.01.008_bib44","first-page":"225","article-title":"Second-generation antipsychotic use in schizophrenia and associated weight gain: a critical review and meta-analysis of behavioral and pharmacologic treatments","volume":"3","author":"Das","year":"2012","journal-title":"Ann Clin Psychiatry"},{"issue":"1\u20133","key":"10.1016\/j.psc.2016.01.008_bib45","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/j.schres.2007.03.029","article-title":"Metformin as an adjunctive treatment to\u00a0control body weight and metabolic dysfunction during olanzapine administration: a multicentric, double-blind, placebo-controlled trial","volume":"93","author":"Baptista","year":"2007","journal-title":"Schizophr Res"},{"key":"10.1016\/j.psc.2016.01.008_bib46","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1176\/appi.ajp.2007.07010079","article-title":"Metformin addition attenuates olazapine-induced weight gain in drug-naive first-episode schizophrenia patients: a double-blind, placebo-controlled study","volume":"3","author":"Wu","year":"2008","journal-title":"Am J Psychiatry"},{"key":"10.1016\/j.psc.2016.01.008_bib47","first-page":"185","article-title":"Lifestyle intervention and metformin for treatment of antipsychotic-induced weight gain: a randomized controlled trial","volume":"2","author":"Wu","year":"2008","journal-title":"JAMA"},{"issue":"9","key":"10.1016\/j.psc.2016.01.008_bib48","doi-asserted-by":"crossref","first-page":"1032","DOI":"10.1176\/appi.ajp.2013.12010127","article-title":"Metformin for weight loss and metabolic control in overweight outpatients with schizophrenia and schizoaffective disorder","volume":"170","author":"Jarskog","year":"2013","journal-title":"AM J Psychiatry"},{"key":"10.1016\/j.psc.2016.01.008_bib49","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1097\/01.wnf.0000172994.56028.c3","article-title":"Topiramate as an adjuvant treatment with atypical antipsychotics in schizophrenic patients experiencing weight gain","volume":"4","author":"Ko","year":"2005","journal-title":"Clin neuropharmacology"},{"issue":"5","key":"10.1016\/j.psc.2016.01.008_bib50","doi-asserted-by":"crossref","first-page":"706","DOI":"10.4088\/JCP.v69n0503","article-title":"Orlistat in clozapine- or olanzapine-treated patients with overweight or obesity: a 16-week randomized, double-blind, placebo-controlled trial","volume":"69","author":"Joffe","year":"2008","journal-title":"J\u00a0Clin Psychiatry"},{"issue":"1\u20132","key":"10.1016\/j.psc.2016.01.008_bib51","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1016\/j.psychres.2008.01.011","article-title":"Metformin plus sibutramine for olanzapine-associated weight gain and metabolic dysfunction in schizophrenia: a 12-week double-blind, placebo-controlled pilot study","volume":"159","author":"Baptista","year":"2008","journal-title":"Psychiatry Res"},{"key":"10.1016\/j.psc.2016.01.008_bib52","doi-asserted-by":"crossref","first-page":"954","DOI":"10.1176\/appi.ajp.162.5.954","article-title":"A\u00a0double-blind, placebo-controlled trial of sibutramine for olanzapine-associated weight gain","volume":"5","author":"Henderson","year":"2005","journal-title":"Am J Psychiatry"},{"key":"10.1016\/j.psc.2016.01.008_bib53","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1111\/j.1600-0447.2006.00855.x","article-title":"A\u00a0double-blind, placebo-controlled trial of sibutramine for clozapine-associated weight gain","volume":"2","author":"Henderson","year":"2007","journal-title":"Acta Psychiatr Scand"},{"key":"10.1016\/j.psc.2016.01.008_bib54","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1177\/0269881105058379","article-title":"Diabetes and schizophrenia 2005: are we any closer to understanding the link?","volume":"6","author":"Holt","year":"2005","journal-title":"J\u00a0Psychopharmacol"},{"key":"10.1016\/j.psc.2016.01.008_bib55","first-page":"79","article-title":"Diabetes mellitus and severe mental illness: mechanisms and clinical implications. Nature reviews","volume":"2","author":"Holt","year":"2014","journal-title":"Endocrinology"},{"key":"10.1016\/j.psc.2016.01.008_bib56","doi-asserted-by":"crossref","first-page":"969182","DOI":"10.1155\/2015\/969182","article-title":"An overview of diabetes management in schizophrenia patients: office based strategies for primary care practitioners and endocrinologists","volume":"2015","author":"Annamalai","year":"2015","journal-title":"Int J Endocrinol"},{"key":"10.1016\/j.psc.2016.01.008_bib57","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1111\/j.1464-5491.2007.02092.x","article-title":"Impaired glucose tolerance in first-episode drug-naive patients with schizophrenia","volume":"5","author":"Spelman","year":"2007","journal-title":"Diabet Med"},{"key":"10.1016\/j.psc.2016.01.008_bib58","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1176\/appi.ajp.160.2.290","article-title":"Changes in glucose and cholesterol levels in patients with schizophrenia treated with typical or atypical antipsychotics","volume":"2","author":"Lindenmayer","year":"2003","journal-title":"Am J Psychiatry"},{"issue":"10","key":"10.1016\/j.psc.2016.01.008_bib59","doi-asserted-by":"crossref","first-page":"1593","DOI":"10.1345\/aph.1K141","article-title":"Risk of treatment-emergent diabetes mellitus in patients receiving antipsychotics","volume":"41","author":"Citrome","year":"2007","journal-title":"Ann Pharmacother"},{"key":"10.1016\/j.psc.2016.01.008_bib60","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1111\/j.1463-1326.2005.00495.x","article-title":"Association between antipsychotic drugs and diabetes","volume":"2","author":"Holt","year":"2006","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.psc.2016.01.008_bib61","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1016\/S0006-3223(98)00100-0","article-title":"Novel antipsychotics and new onset diabetes","volume":"44","author":"Wirshing","year":"1998","journal-title":"Biol Psychiatry"},{"key":"10.1016\/j.psc.2016.01.008_bib62","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/S1098-3597(08)60025-3","article-title":"Obesity, abdominal obesity, and insulin resistance","volume":"1","author":"Westphal","year":"2008","journal-title":"Clin cornerstone"},{"key":"10.1016\/j.psc.2016.01.008_bib63","doi-asserted-by":"crossref","first-page":"1686","DOI":"10.1176\/ajp.156.11.1686","article-title":"Antipsychotic-induced weight gain: a comprehensive research synthesis","volume":"11","author":"Allison","year":"1999","journal-title":"Am J Psychiatry"},{"key":"10.1016\/j.psc.2016.01.008_bib64","doi-asserted-by":"crossref","first-page":"3232","DOI":"10.2337\/db13-0430","article-title":"Antipsychotic-induced insulin resistance and postprandial hormonal dysregulation independent of weight gain or psychiatric disease","volume":"9","author":"Teff","year":"2013","journal-title":"Diabetes"},{"key":"10.1016\/j.psc.2016.01.008_bib65","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1097\/JCP.0b013e3180cac8db","article-title":"Sex difference in effects of typical and atypical antipsychotics on glucose-insulin homeostasis and lipid metabolism in first-episode schizophrenia","volume":"4","author":"Wu","year":"2007","journal-title":"J\u00a0Clin Psychopharmacol"},{"key":"10.1016\/j.psc.2016.01.008_bib66","doi-asserted-by":"crossref","first-page":"1501","DOI":"10.4088\/JCP.08m04446yel","article-title":"Effects of olanzapine and risperidone on glucose metabolism and insulin sensitivity in chronic schizophrenic patients with long-term antipsychotic treatment: a randomized 5-month study","volume":"11","author":"Smith","year":"2009","journal-title":"J\u00a0Clin Psychiatry"},{"key":"10.1016\/j.psc.2016.01.008_bib67","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1016\/j.cmet.2006.04.009","article-title":"A\u00a0critical role for beta cell M3 muscarinic acetylcholine receptors in regulating insulin release and blood glucose homeostasis in\u00a0vivo","volume":"6","author":"Gautam","year":"2006","journal-title":"Cell Metab"},{"issue":"3","key":"10.1016\/j.psc.2016.01.008_bib68","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1016\/j.eurpsy.2009.01.001","article-title":"How can antipsychotics cause Diabetes Mellitus? Insights based on receptor-binding profiles, humoral factors and transporter proteins","volume":"24","author":"Starrenburg","year":"2009","journal-title":"Eur Psychiatry"},{"key":"10.1016\/j.psc.2016.01.008_bib69","doi-asserted-by":"crossref","first-page":"S12","DOI":"10.1016\/S0924-9338(10)71701-6","article-title":"From receptor pharmacology to improved outcomes: individualising the selection, dosing, and switching of antipsychotics","volume":"25","author":"Correll","year":"2010","journal-title":"Eur Psychiatry"},{"key":"10.1016\/j.psc.2016.01.008_bib70","doi-asserted-by":"crossref","first-page":"856","DOI":"10.4088\/JCP.v63n1002","article-title":"The effects of novel antipsychotics on glucose and lipid levels","volume":"10","author":"Wirshing","year":"2002","journal-title":"J\u00a0Clin Psychiatry"},{"key":"10.1016\/j.psc.2016.01.008_bib71","doi-asserted-by":"crossref","first-page":"17","DOI":"10.4103\/0976-3147.143182","article-title":"Diabetes mellitus and impaired glucose tolerance in patients with schizophrenia, before and after antipsychotic treatment","volume":"1","author":"Wani","year":"2015","journal-title":"J\u00a0neurosciences Rural Pract"},{"key":"10.1016\/j.psc.2016.01.008_bib72","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1192\/bjp.bp.107.045732","article-title":"Quality of medical care for people with and without comorbid mental illness and substance misuse: systematic review of comparative studies","volume":"6","author":"Mitchell","year":"2009","journal-title":"Br J Psychiatry"},{"key":"10.1016\/j.psc.2016.01.008_bib73","doi-asserted-by":"crossref","first-page":"S4","DOI":"10.2337\/dc15-S003","article-title":"Standards of medical care in diabetes\u20132015: summary of revisions","volume":"38","year":"2015","journal-title":"Diabetes care"},{"issue":"1\u20133","key":"10.1016\/j.psc.2016.01.008_bib74","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.schres.2006.06.026","article-title":"Low rates of treatment for hypertension, dyslipidemia and diabetes in schizophrenia: data from the CATIE schizophrenia trial sample at baseline","volume":"86","author":"Nasrallah","year":"2006","journal-title":"Schizophr Res"},{"key":"10.1016\/j.psc.2016.01.008_bib75","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1194\/jlr.E034736","article-title":"Antipsychotic-induced increase in lipid biosynthesis: activation through inhibition","volume":"54","author":"Skrede","year":"2013","journal-title":"J\u00a0Lipid Res"},{"issue":"1","key":"10.1016\/j.psc.2016.01.008_bib76","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.schres.2004.01.014","article-title":"The effects of antipsychotic therapy on serum lipids: a comprehensive review","volume":"70","author":"Meyer","year":"2004","journal-title":"Schizophr Res"},{"issue":"4","key":"10.1016\/j.psc.2016.01.008_bib77","doi-asserted-by":"crossref","first-page":"547","DOI":"10.4088\/JCP.v65n0415","article-title":"Hyperlipidemia in persons using antipsychotic medication: a general population-based birth cohort study","volume":"65","author":"Saari","year":"2004","journal-title":"J\u00a0Clin Psychiatry"},{"issue":"5","key":"10.1016\/j.psc.2016.01.008_bib78","first-page":"331","article-title":"Changes in serum lipids, independent of weight, are associated with changes in symptoms during long-term clozapine treatment","volume":"32","author":"Procyshyn","year":"2007","journal-title":"J\u00a0Psychiatry Neurosci"},{"issue":"2","key":"10.1016\/j.psc.2016.01.008_bib79","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1097\/00002826-199903000-00006","article-title":"The impact of clozapine treatment on serum lipids in chronic schizophrenic patients","volume":"22","author":"Spivak","year":"1999","journal-title":"Clin Neuropharmacol"},{"issue":"4","key":"10.1016\/j.psc.2016.01.008_bib80","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1590\/S1516-44462006005000016","article-title":"Increased dyslipidemia in schizophrenic outpatients using new generation antipsychotics","volume":"28","author":"Leit\u00e3o-Azevedo","year":"2006","journal-title":"Rev Bras Psiquiatr"},{"key":"10.1016\/j.psc.2016.01.008_bib81","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1038\/clpt.1985.113","article-title":"Lipids and apolipoproteins in patients treated with major tranquilizers","volume":"37","author":"Sasaki","year":"1985","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.psc.2016.01.008_bib82","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.schres.2007.01.015","article-title":"A\u00a0clinical study of the association of antipsychotics with hyperlipidemia","volume":"92","author":"de Leon","year":"2007","journal-title":"Schizophr Res"},{"key":"10.1016\/j.psc.2016.01.008_bib83","doi-asserted-by":"crossref","first-page":"1821","DOI":"10.1176\/ajp.2006.163.10.1821","article-title":"Hyperlipidemia following treatment with antipsychotic medications","volume":"163","author":"Olfson","year":"2006","journal-title":"Am J Psychiatry"},{"issue":"5","key":"10.1016\/j.psc.2016.01.008_bib84","doi-asserted-by":"crossref","first-page":"817","DOI":"10.4088\/JCP.v69n0515","article-title":"Efficacy and tolerability of oral paliperidone extended-release tablets in the treatment of acute schizophrenia: pooled data from three 6-week, placebo-controlled studies","volume":"69","author":"Meltzer","year":"2008","journal-title":"J\u00a0Clin Psychiatry"},{"issue":"2 Suppl 1","key":"10.1016\/j.psc.2016.01.008_bib85","doi-asserted-by":"crossref","first-page":"S12","DOI":"10.1097\/JCP.0b013e3181694f5a","article-title":"Safety profile of iloperidone: a pooled analysis of 6-week acute-phase pivotal trials","volume":"28","author":"Weiden","year":"2008","journal-title":"J\u00a0Clin Psychopharmacol"},{"issue":"3","key":"10.1016\/j.psc.2016.01.008_bib86","doi-asserted-by":"crossref","first-page":"238","DOI":"10.4088\/JCP.12m08271","article-title":"Weight Change and Metabolic Effects of Asenapine in Patients With Schizophrenia and Bipolar Disorder","volume":"75","author":"Kemp","year":"2014","journal-title":"J\u00a0Clin Psychiatry"},{"issue":"2\u20133","key":"10.1016\/j.psc.2016.01.008_bib87","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/j.schres.2011.04.008","article-title":"Double-blind comparison of the safety and efficacy of lurasidone and ziprasidone in clinically stable outpatients with schizophrenia or schizoaffective disorder","volume":"132","author":"Potkin","year":"2011","journal-title":"Schizophr Res"},{"key":"10.1016\/j.psc.2016.01.008_bib88","doi-asserted-by":"crossref","first-page":"239","DOI":"10.2147\/TCRM.S12701","article-title":"Clinical potential of lurasidone in the management of schizophrenia","volume":"7","author":"Samalin","year":"2011","journal-title":"Ther Clin Risk Manag"},{"key":"10.1016\/j.psc.2016.01.008_bib89","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1331\/JAPhA.2007.06090","article-title":"Effect on lipid profiles of switching from olanzapine to another second-generation antipsychotic agent in veterans with schizophrenia","volume":"47","author":"Garman","year":"2007","journal-title":"J\u00a0Am Pharm Assoc"},{"key":"10.1016\/j.psc.2016.01.008_bib90","doi-asserted-by":"crossref","first-page":"1161","DOI":"10.1001\/archpsyc.58.12.1161","article-title":"Antipsychotics and the risk of sudden cardiac death","volume":"58","author":"Ray","year":"2001","journal-title":"Arch Gen Psychiatry"},{"key":"10.1016\/j.psc.2016.01.008_bib91","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1111\/j.1600-0447.2005.00592.x","article-title":"Torsade de pointes in a patient with complex medical and psychiatric conditions receiving low-dose quetiapine","volume":"112","author":"Vieweg","year":"2005","journal-title":"Acta Psychiatr Scand"},{"key":"10.1016\/j.psc.2016.01.008_bib92","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1176\/appi.psy.45.5.450","article-title":"Torsades de pointes caused by a small dose of risperidone in a terminally ill cancer patient","volume":"45","author":"Tei","year":"2004","journal-title":"Psychosomatics"},{"key":"10.1016\/j.psc.2016.01.008_bib93","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1176\/appi.psy.47.3.264","article-title":"Torsades de pointes associated with ziprasidone","volume":"47","author":"Heinrich","year":"2006","journal-title":"Psychosomatics"},{"key":"10.1016\/j.psc.2016.01.008_bib94","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1056\/NEJMoa0806994","article-title":"Atypical antipsychotic drugs and the risk of sudden cardiac death","volume":"360","author":"Ray","year":"2009","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.psc.2016.01.008_bib95","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1016\/j.ahj.2015.01.007","article-title":"Cardiovascular safety outcomes trials: a meeting report from the cardiac safety research consortium","volume":"169","author":"Sager","year":"2015","journal-title":"Am Heart J"},{"key":"10.1016\/j.psc.2016.01.008_bib96","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.psym.2012.11.001","article-title":"QTc interval prolongation, torsades de pointes, and psychotropic medications","volume":"54","author":"Beach","year":"2013","journal-title":"Psychosomatics"},{"key":"10.1016\/j.psc.2016.01.008_bib97","doi-asserted-by":"crossref","first-page":"35","DOI":"10.2165\/00002018-200528010-00003","article-title":"Atypical antipsychotics from potassium channels to torsade de pointes and sudden death","volume":"28","author":"Titier","year":"2005","journal-title":"Drug Saf"},{"key":"10.1016\/j.psc.2016.01.008_bib98","doi-asserted-by":"crossref","first-page":"1649","DOI":"10.2165\/00003495-200262110-00006","article-title":"Antipsychotic-related QTc interval prolongation, torsade de points and sudden death","volume":"62","author":"Haddad","year":"2002","journal-title":"Drugs"},{"key":"10.1016\/j.psc.2016.01.008_bib99","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1111\/bcp.12040","article-title":"Drug induced QT prolongation: the measurement and assessment of the QT interval in practice","volume":"76","author":"Isbister","year":"2012","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.psc.2016.01.008_bib100","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1592\/phco.23.7.881.32730","article-title":"Clinical relevance and management of drug-related QT interval prolongation","volume":"23","author":"Crouch","year":"2003","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.psc.2016.01.008_bib101","doi-asserted-by":"crossref","first-page":"1831","DOI":"10.1136\/heartjnl-2014-305671","article-title":"Short-term QT variability markers for the prediction of ventricular arrhythmias and sudden cardiac death: a systematic review","volume":"100","author":"Niemeijer","year":"2014","journal-title":"Heart"},{"key":"10.1016\/j.psc.2016.01.008_bib102","doi-asserted-by":"crossref","first-page":"97","DOI":"10.2174\/157488610789869265","article-title":"QT alterations in psychopharmacology: proven candidates and suspects","volume":"5","author":"Alvarez","year":"2010","journal-title":"Curr Drug Saf"},{"key":"10.1016\/j.psc.2016.01.008_bib103","doi-asserted-by":"crossref","first-page":"e001568","DOI":"10.1161\/JAHA.114.001568","article-title":"Antipsychotic drugs and the risk of ventricular arrhythmia and\/or sudden cardiac death: a nation-wide case-crossover study","volume":"4","author":"Wu","year":"2015","journal-title":"J\u00a0Am Heart Assoc"},{"key":"10.1016\/j.psc.2016.01.008_bib104","doi-asserted-by":"crossref","first-page":"247486","DOI":"10.1155\/2013\/247486","article-title":"Risk of mortality (including sudden cardiac death) and major cardiovascular events in atypical and typical antipsychotic users: a study with the general practice research database","volume":"2013","author":"Murray-Thomas","year":"2013","journal-title":"Cardiovasc Psychiatry Neurol"},{"key":"10.1016\/j.psc.2016.01.008_bib105","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1038\/clpt.2014.139","article-title":"Antipsychotics and associated risk of out-of-hospital cardiac arrest","volume":"96","author":"Weeke","year":"2014","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.psc.2016.01.008_bib106","doi-asserted-by":"crossref","first-page":"1719","DOI":"10.1185\/03007995.2013.840568","article-title":"QT interval prolongation and the risk of torsades de pointes: essentials for clinicians","volume":"29","author":"Trinkley","year":"2013","journal-title":"Curr Med Res Opin"},{"key":"10.1016\/j.psc.2016.01.008_bib107","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1080\/08039480801959323","article-title":"Schizophrenia and sudden cardiac death - a review","volume":"62","author":"Koponen","year":"2008","journal-title":"Nord J Psychiatry"},{"key":"10.1016\/j.psc.2016.01.008_bib108","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1097\/01.pra.0000450319.21859.6d","article-title":"QTc interval prolongation with antipsychotics: is routine ECG monitoring recommended?","volume":"20","author":"Shah","year":"2014","journal-title":"J\u00a0Psychiatr Pract"},{"key":"10.1016\/j.psc.2016.01.008_bib109","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1155\/2014\/273060","article-title":"Minimizing cardiovascular adverse effects of atypical antipsychotic drugs in patients with schizophrenia","volume":"2014","author":"Khasawneh","year":"2014","journal-title":"Cardiol Res Pract"},{"key":"10.1016\/j.psc.2016.01.008_bib110","doi-asserted-by":"crossref","first-page":"S11","DOI":"10.1007\/s40263-012-0029-7","article-title":"Augmentation treatments with second-generation antipsychotics to antidepressants in treatment-resistant depression","volume":"27","author":"Kato","year":"2013","journal-title":"CNS Drugs"},{"key":"10.1016\/j.psc.2016.01.008_bib111","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1002\/phar.1204","article-title":"Augmentation with atypical antipsychotics for depression: a review of evidence-based support from the medical literature","volume":"33","author":"Wright","year":"2013","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.psc.2016.01.008_bib112","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1517\/17425255.2014.885504","article-title":"Clinically relevant interactions between newer antidepressants and second-generation antipsychotics","volume":"10","author":"Spina","year":"2014","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"10.1016\/j.psc.2016.01.008_bib113","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1186\/s12888-015-0416-y","article-title":"Screening for cardiovascular risk factors in adults with serious mental illness: a review of the evidence","volume":"15","author":"Baller","year":"2015","journal-title":"BMC Psychiatry"},{"key":"10.1016\/j.psc.2016.01.008_bib114","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.jaac.2014.10.002","article-title":"Corrected QT changes during antipsychotic treatment of children and adolescents: a systematic review and meta-analysis of clinical trials","volume":"54","author":"Jensen","year":"2015","journal-title":"J\u00a0Am Acad Child Adolesc Psychiatry"},{"key":"10.1016\/j.psc.2016.01.008_bib115","first-page":"CD006569","article-title":"Aripiprazole versus other atypical antipsychotics for schizophrenia","volume":"1","author":"Khanna","year":"2014","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.psc.2016.01.008_bib116","first-page":"CD006625","article-title":"Quetiapine versus other atypical antipsychotics for schizophrenia","volume":"11","author":"Asmal","year":"2013","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.psc.2016.01.008_bib117","first-page":"CD006626","article-title":"Risperidone versus other atypical antipsychotics for schizophrenia","volume":"1","author":"Komossa","year":"2011","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.psc.2016.01.008_bib118","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1345\/aph.1M603","article-title":"Iloperidone for the treatment of schizophrenia","volume":"44","author":"Marino","year":"2010","journal-title":"Ann Pharmacother"},{"key":"10.1016\/j.psc.2016.01.008_bib119","first-page":"803","article-title":"Asenapine review, part II: clinical efficacy, safety and tolerability","volume":"13","author":"Citrome","year":"2014","journal-title":"Expert Opin Drug Saf"},{"key":"10.1016\/j.psc.2016.01.008_bib120","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1007\/s40263-012-0026-x","article-title":"Lurasidone in the treatment of schizophrenia","volume":"27","author":"Sanford","year":"2013","journal-title":"CNS Drugs"},{"key":"10.1016\/j.psc.2016.01.008_bib121","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1111\/j.1742-1241.2010.02587.x","article-title":"Lurasidone for schizophrenia: a review of the efficacy and safety profile for this newly approved second-generation antipsychotic","volume":"65","author":"Citrome","year":"2011","journal-title":"Int J Clin Pract"},{"key":"10.1016\/j.psc.2016.01.008_bib122","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1007\/s40263-013-0083-9","article-title":"Long-acting injectable formulations of new-generation antipsychotics: a review from a clinical perspective","volume":"27","author":"Rauch","year":"2013","journal-title":"CNS Drugs"},{"key":"10.1016\/j.psc.2016.01.008_bib123","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.1002\/phar.1313","article-title":"Adverse effects associated with second-generation antipsychotic long-acting injection treatment: a comprehensive systematic review","volume":"33","author":"Gentile","year":"2013","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.psc.2016.01.008_bib124","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1097\/YIC.0b013e32835b091f","article-title":"Efficacy and safety of second-generation long-acting injections in schizophrenia: a meta-analysis fo randomized-controlled trials","volume":"28","author":"Fusar-Poli","year":"2013","journal-title":"Int Clin Psychopharmacol"},{"key":"10.1016\/j.psc.2016.01.008_bib125","doi-asserted-by":"crossref","first-page":"869","DOI":"10.2217\/pgs.14.50","article-title":"Pharmacogenetics of second-generation antipsychotics","volume":"15","author":"Brennan","year":"2014","journal-title":"Pharmacogenomics"},{"issue":"23","key":"10.1016\/j.psc.2016.01.008_bib126","doi-asserted-by":"crossref","first-page":"2071","DOI":"10.1161\/CIR.0000000000000040","article-title":"AHA\/ACC\/HRS practice guideline: 2014 AHA\/ACC\/HRS guideline for the management of patients with atrial fibrillation: executive summary","volume":"130","author":"January","year":"2014","journal-title":"Circulation"},{"key":"10.1016\/j.psc.2016.01.008_bib127","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1161\/CIRCOUTCOMES.113.000152","article-title":"Development and validation of a risk score to predict QT interval prolongation in hospitalized patients","volume":"6","author":"Tisdale","year":"2013","journal-title":"Circ Cardiovasc Qual Outcomes"},{"issue":"25 Suppl 2","key":"10.1016\/j.psc.2016.01.008_bib128","doi-asserted-by":"crossref","first-page":"S49","DOI":"10.1161\/01.cir.0000437741.48606.98","article-title":"2013 ACC\/AHA guideline on the\u00a0assessment of cardiovascular risk: a report of the American College of Cardiology\/American Heart Association Task Force on Practice Guidelines","volume":"129","author":"Goff","year":"2014","journal-title":"Circulation"},{"key":"10.1016\/j.psc.2016.01.008_bib129","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1146\/annurev-clinpsy-032813-153657","article-title":"Excess early mortality in schizophrenia","volume":"10","author":"Laursen","year":"2014","journal-title":"Annu Rev Clin Psychol"},{"key":"10.1016\/j.psc.2016.01.008_bib130","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1001\/archpsyc.64.10.1123","article-title":"A\u00a0systematic review of mortality in schizophrenia: is the differential mortality gap worsening over time?","volume":"64","author":"Saha","year":"2007","journal-title":"Arch Gen Psychiatry"},{"key":"10.1016\/j.psc.2016.01.008_bib131","first-page":"297","article-title":"Healthcare providers\u2019 attitudes towards persons with schizophrenia","volume":"37","author":"Mittal","year":"2014","journal-title":"Psychiatr Res J"},{"key":"10.1016\/j.psc.2016.01.008_bib132","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/j.euroneuro.2009.12.002","article-title":"The risk of death among adult participants in trials of antipsychotic drugs in schizophrenia","volume":"20","author":"Isaac","year":"2010","journal-title":"Eur Neuropsychopharmacol"},{"key":"10.1016\/j.psc.2016.01.008_bib133","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.schres.2009.05.018","article-title":"Influence of antipsychotics on mortality in schizophrenia: systematic review","volume":"113","author":"Weinmann","year":"2009","journal-title":"Schizophr Res"},{"key":"10.1016\/j.psc.2016.01.008_bib134","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1016\/S0140-6736(09)60742-X","article-title":"11-year follow-up of mortality in patients with schizophrenia: a population-based cohort study (FINA11 study)","volume":"374","author":"Tiihonen","year":"2009","journal-title":"Lancet"},{"key":"10.1016\/j.psc.2016.01.008_bib135","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/j.schres.2009.12.029","article-title":"Do antipsychotic medications reduce or increase mortality in schizophrenia? A critical appraisal of the FIN-11 study","volume":"117","author":"De Hert","year":"2010","journal-title":"Schizophr Res"},{"key":"10.1016\/j.psc.2016.01.008_bib136","doi-asserted-by":"crossref","first-page":"647476","DOI":"10.1155\/2013\/647476","article-title":"Risk of mortality (including sudden cardiac death) and major cardiovascular events in users of olanzapine and other antipsychotics: a study with the General Practice Research Database","volume":"2013","author":"Jones","year":"2013","journal-title":"Cardiovasc Psychiatry Neurol"},{"key":"10.1016\/j.psc.2016.01.008_bib137","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1001\/jamapsychiatry.2013.149","article-title":"Comparative mortality risk in adult patients with schizophrenia, depression, bipolar disorder, anxiety disorders, and attention-deficit\/hyperactivity disorder participating in psychopharmacology trials","volume":"70","author":"Khan","year":"2013","journal-title":"JAMA Psychiatry"},{"key":"10.1016\/j.psc.2016.01.008_bib138","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1093\/schbul\/sbu164","article-title":"Antipsychotic treatment and mortality in schizophrenia","volume":"41","author":"Torniainen","year":"2015","journal-title":"Schizophr Bull"},{"key":"10.1016\/j.psc.2016.01.008_bib139","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1097\/JCP.0b013e31823f3c43","article-title":"All-cause mortality and medication risk factors in schizophrenia: A prospective cohort study","volume":"32","author":"Tenback","year":"2012","journal-title":"J\u00a0Clin Psychopharmacol"},{"issue":"6","key":"10.1016\/j.psc.2016.01.008_bib140","first-page":"1","article-title":"Antipsychotics and the risks of sudden cardiac death and all-cause death: cohort studies in medicaid and dually eligible medicaid-medicare beneficiaries of five states","volume":"10","author":"Leonard","year":"2013","journal-title":"J\u00a0Clinic Exp Cardiol"},{"key":"10.1016\/j.psc.2016.01.008_bib141","doi-asserted-by":"crossref","first-page":"91","DOI":"10.2165\/00023210-200519020-00001","article-title":"Do atypical antipsychotics cause stroke?","volume":"19","author":"Herrmann","year":"2005","journal-title":"CNS Drugs"},{"key":"10.1016\/j.psc.2016.01.008_bib142","doi-asserted-by":"crossref","first-page":"1934","DOI":"10.1001\/jama.294.15.1934","article-title":"Risk of death with atypical antipsychotic drug treatment for dementia: meta-analysis of randomized placebo-controlled trials","volume":"294","author":"Schneider","year":"2005","journal-title":"JAMA"},{"key":"10.1016\/j.psc.2016.01.008_bib143","unstructured":"FDA. Public health advisory: deaths with antipsychotics in elderly patients with\u00a0behavioral disturbances. 2005. Available at: http:\/\/www.fda.gov\/Drugs\/DrugSafety\/PostmarketDrugSafetyInformationforPatientsandProviders\/ucm053171.htm. Accessed February 23, 2016."},{"key":"10.1016\/j.psc.2016.01.008_bib144","doi-asserted-by":"crossref","first-page":"1359","DOI":"10.1001\/jama.2011.1360","article-title":"Efficacy and comparative effectiveness of atypical antipsychotic medications for off-label uses in adults: a systematic review and meta-analysis","volume":"306","author":"Maher","year":"2011","journal-title":"JAMA"},{"key":"10.1016\/j.psc.2016.01.008_bib145","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1186\/s13195-015-0102-9","article-title":"Efficacy and safety of atypical antipsychotic drug treatment for dementia: a systematic review and meta-analysis","volume":"7","author":"Tan","year":"2015","journal-title":"Alzheimers Res Ther"},{"key":"10.1016\/j.psc.2016.01.008_bib146","doi-asserted-by":"crossref","first-page":"775","DOI":"10.7326\/0003-4819-146-11-200706050-00006","article-title":"Antipsychotic drug use and mortality in older adults with dementia","volume":"146","author":"Gill","year":"2007","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.psc.2016.01.008_bib147","doi-asserted-by":"crossref","first-page":"1058","DOI":"10.1017\/S1041610212000117","article-title":"Effect of comorbidity on the risk of death associated with antipsychotic use among community-dwelling older adults","volume":"24","author":"Gisev","year":"2012","journal-title":"Int Psychogeriatr"},{"key":"10.1016\/j.psc.2016.01.008_bib148","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1186\/1471-2288-12-72","article-title":"Choice of observational study design impacts on measurement of antipsychotic risks in the elderly: a systematic review","volume":"12","author":"Pratt","year":"2012","journal-title":"BMC Med Res Methodol"},{"key":"10.1016\/j.psc.2016.01.008_bib149","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1176\/appi.ajp.2008.07111779","article-title":"Clinical symptom responses to atypical antipsychotic medications in Alzheimer\u2019s disease: phase 1 outcomes from the CATIE-AD effectiveness trial","volume":"165","author":"Sultzer","year":"2008","journal-title":"Am J Psychiatry"},{"key":"10.1016\/j.psc.2016.01.008_bib150","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1001\/jamapsychiatry.2014.3018","article-title":"Antipsychotics, other psychotropics, and the risk of death in patients with dementia: number needed to harm","volume":"72","author":"Maust","year":"2015","journal-title":"JAMA Psychiatry"},{"issue":"10","key":"10.1016\/j.psc.2016.01.008_bib151","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1016\/j.jamda.2015.03.015","article-title":"The mortality risk of conventional antipsychotics in elderly patients: a systematic review and meta-analysis of randomized placebo-controlled trials","volume":"16","author":"Hulshof","year":"2015","journal-title":"J\u00a0Am Med Dir Assoc"},{"key":"10.1016\/j.psc.2016.01.008_bib152","first-page":"1","article-title":"Risk of death is elderly users of conventional vs. atypical antipsychotic medications","volume":"113","author":"Wang","year":"2005","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.psc.2016.01.008_bib153","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1503\/cmaj.061250","article-title":"Risk of death associated with the use of conventional versus atypical antipsychotic drugs among elderly patients","volume":"176","author":"Schneeweiss","year":"2007","journal-title":"CMAJ"},{"key":"10.1016\/j.psc.2016.01.008_bib154","doi-asserted-by":"crossref","first-page":"1340","DOI":"10.4088\/JCP.08m04597yel","article-title":"All-cause mortality associated with atypical and conventional antipsychotic among nursing home residents with dementia: a retrospective cohort study","volume":"70","author":"Liperoti","year":"2009","journal-title":"J\u00a0Clin Psychiatry"},{"key":"10.1016\/j.psc.2016.01.008_bib155","doi-asserted-by":"crossref","first-page":"1644","DOI":"10.1111\/j.1532-5415.2008.01839.x","article-title":"Potential causes of higher mortality in elderly users of conventional and atypical antipsychotic medications","volume":"56","author":"Setoguchi","year":"2008","journal-title":"J\u00a0Am Geriatr Soc"},{"key":"10.1016\/j.psc.2016.01.008_bib156","doi-asserted-by":"crossref","first-page":"e977","DOI":"10.1136\/bmj.e977","article-title":"Differential risk of death in older residents in nursing homes prescribed specific antipsychotic drugs: population based cohort study","volume":"344","author":"Huybrechts","year":"2012","journal-title":"BMJ"},{"key":"10.1016\/j.psc.2016.01.008_bib157","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1097\/MLR.0b013e31826ec185","article-title":"Risk of death in dual-eligible nursing home residents using typical or atypical antipsychotic agents","volume":"50","author":"Aparasu","year":"2012","journal-title":"Med Care"},{"key":"10.1016\/j.psc.2016.01.008_bib158","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1176\/appi.ajp.2011.11030347","article-title":"Risk of mortality among individual antipsychotics in patients with dementia","volume":"169","author":"Kales","year":"2012","journal-title":"Am J Psychiatry"},{"key":"10.1016\/j.psc.2016.01.008_bib159","unstructured":"FDA. Information for healthcare professionals: conventional antipsychotics. 2008. Available at: http:\/\/www.fda.gov\/Drugs\/DrugSafety\/PostmarketDrugSafetyInformationforPatientsandProviders\/ucm124830.htm. Accessed February 23, 2016."},{"key":"10.1016\/j.psc.2016.01.008_bib160","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1093\/aje\/kwu210","article-title":"The explanatory role of stroke as mediator of the mortality risk difference between older adults who initiate first- versus second-generation antipsychotic drugs","volume":"180","author":"Jackson","year":"2014","journal-title":"Am J Epidemiol"},{"key":"10.1016\/j.psc.2016.01.008_bib161","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1016\/j.jalz.2011.08.004","article-title":"Impact of the Food and Drug Administration\u2019s antipsychotic black box warning on psychotropic drug prescribing in elderly patients with dementia in outpatient and office-based settings","volume":"8","author":"Desai","year":"2012","journal-title":"Alzheimers Dement"},{"key":"10.1016\/j.psc.2016.01.008_bib162","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1176\/appi.focus.11.1.32","article-title":"The role of antipsychotic drugs in the treatment of neuropsychiatric symptoms of dementia","volume":"11","author":"Keenmon","year":"2013","journal-title":"Focus"},{"key":"10.1016\/j.psc.2016.01.008_bib163","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1192\/bjp.bp.113.141119","article-title":"Non-pharmacologic interventions for agitation in dementia: systematic review of randomized controlled trials","volume":"205","author":"Livingston","year":"2015","journal-title":"BR J Psychiatry"},{"issue":"3","key":"10.1016\/j.psc.2016.01.008_bib164","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD007726.pub2","article-title":"Withdrawal versus continuation of chronic antipsychotic drugs for behavioural and psychological symptoms in older people with dementia","author":"Declercq","year":"2013","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.psc.2016.01.008_bib165","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1159\/000355418","article-title":"Antipsychotic discontinuation in patients with dementia: a systematic review and meta-analysis of published randomized controlled studies","volume":"37","author":"Pan","year":"2014","journal-title":"Dement Geriatr Cogn Disord"},{"key":"10.1016\/j.psc.2016.01.008_bib166","first-page":"361","article-title":"Antipsychotic-induced hyperprolactinemia","volume":"68","author":"Inder","year":"2011","journal-title":"Aust N Z J Psychiatry"},{"key":"10.1016\/j.psc.2016.01.008_bib167","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/S0306-4530(02)00127-0","article-title":"Prevalence of hyperprolactinemia in schizophrenic patients treated with conventional antipsychotic medications or risperidone","volume":"28","author":"Kinon","year":"2003","journal-title":"Psychoneuroendocrinology"},{"key":"10.1016\/j.psc.2016.01.008_bib168","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1177\/0269881107088435","article-title":"A\u00a0review of the association between antipsychotic use and hyperporolactinaemia","volume":"22","author":"Bushe","year":"2008","journal-title":"J\u00a0Psycholpharmacol"},{"issue":"3","key":"10.1016\/j.psc.2016.01.008_bib169","doi-asserted-by":"crossref","first-page":"253","DOI":"10.5455\/bcp.20131213042842","article-title":"Hyperprolactinemia due to paliperidone palmitate and treatment with aripiprazole","volume":"24","author":"Alpak","year":"2014","journal-title":"Bull Clin Psychopharmacol"},{"key":"10.1016\/j.psc.2016.01.008_bib170","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1177\/0269881112442016","article-title":"Prolactin, hyperprolactinema and antipsychotic treatment: a review and lessons for treatment of early psychosis","volume":"26","author":"Cookson","year":"2012","journal-title":"J\u00a0Psychopharmacol"},{"key":"10.1016\/j.psc.2016.01.008_bib171","doi-asserted-by":"crossref","first-page":"2291","DOI":"10.2165\/00003495-200464200-00003","article-title":"Antipsychotic-induced hyperprolactinemia: mechanisms, clinical features and management","volume":"64","author":"Haddad","year":"2004","journal-title":"Drugs"},{"key":"10.1016\/j.psc.2016.01.008_bib172","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1002\/hup.1116","article-title":"Hyperprolactinemia associated with psychotropics: a review","volume":"25","author":"Madhusoodanan","year":"2010","journal-title":"Hum Psychopharmacol"},{"key":"10.1016\/j.psc.2016.01.008_bib173","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1097\/JCP.0b013e31822cfff2","article-title":"DRD2 Taq1A polymorphism modulates prolactin secretion induced by atypical antipsychotics in healthy volunteers","volume":"31","author":"Lopez-Rodriguez","year":"2011","journal-title":"J\u00a0Clin Psychopharmacol"},{"key":"10.1016\/j.psc.2016.01.008_bib174","first-page":"421","article-title":"The effects of novel and newly approved antipsychotics on serum prolactin levels: a comprehensive review","volume":"28","author":"Peuskens","year":"2014","journal-title":"CNS Drugs"},{"key":"10.1016\/j.psc.2016.01.008_bib175","doi-asserted-by":"crossref","first-page":"1010","DOI":"10.1176\/appi.ajp.162.5.1010","article-title":"Predominant role of the 9-hydroxy metabolite of risperidone in elevating blood prolactin levels","volume":"162","author":"Knegtering","year":"2005","journal-title":"Am J Psychiatry"},{"key":"10.1016\/j.psc.2016.01.008_bib176","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1177\/0269881109106914","article-title":"A\u00a0comparison of serum prolactin concentrations after administration of paliperidone extended-release and risperidone tables in patients with schizophrenia","volume":"24","author":"Berwaerts","year":"2010","journal-title":"J\u00a0Psychopharmacol"},{"key":"10.1016\/j.psc.2016.01.008_bib177","doi-asserted-by":"crossref","first-page":"1491","DOI":"10.4088\/JCP.v65n1108","article-title":"Prevalence of hyperprolactinemia in schizophrenia: association with typical and atypical antipsychotic treatment","volume":"65","author":"Montgomery","year":"2004","journal-title":"J\u00a0Clin Psychiatry"},{"key":"10.1016\/j.psc.2016.01.008_bib178","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1176\/ajp.2006.163.4.600","article-title":"Effectivness of clozapine versus olanzapine, quetiapine, and risperidone in patients with chronic schizophrenia who did not respond to prior atypical antipsychotic treatment","volume":"163","author":"McEvoy","year":"2006","journal-title":"Am J Psychiatry"},{"key":"10.1016\/j.psc.2016.01.008_bib179","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1176\/ajp.2007.164.3.415","article-title":"Effectiveness of olanzapine, quetiapine, and risperidone in patients with chronic schizophrenia after discontinuing perphenazine: A CATIE study","volume":"164","author":"Stroup","year":"2007","journal-title":"Am J Psychiatry"},{"key":"10.1016\/j.psc.2016.01.008_bib180","doi-asserted-by":"crossref","first-page":"1050","DOI":"10.1176\/ajp.2007.164.7.1050","article-title":"Efficacy and tolerability of olanzapine, quetiapine, and risperidone in the treatment of early psychosis: a randomized, double-blind 52-week comparison","volume":"164","author":"McEvoy","year":"2007","journal-title":"Am J Psychiatry"},{"key":"10.1016\/j.psc.2016.01.008_bib181","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1586\/ecp.12.70","article-title":"Asenapine, iloperidone and lurasidone: critical appraisal of the most recently approved pharmacotherapies for schizophrenia in adults","volume":"6","author":"Bobo","year":"2013","journal-title":"Expert Rev Clin Pharmacol"},{"key":"10.1016\/j.psc.2016.01.008_bib182","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1177\/0269881107082944","article-title":"Asenapine: a novel psychopharmacologic agent with a unique human receptor signature","volume":"23","author":"Shahid","year":"2009","journal-title":"J\u00a0Psychopharmacol"},{"key":"10.1016\/j.psc.2016.01.008_bib183","first-page":"325","article-title":"Role of sublingual asenapine in treatment of schizophrenia","volume":"7","author":"Citrome","year":"2011","journal-title":"Neuropsychiatr Dis Treat"},{"key":"10.1016\/j.psc.2016.01.008_bib184","doi-asserted-by":"crossref","first-page":"829","DOI":"10.4088\/JCP.08m04905","article-title":"Lurasidone in the treatment of acute schizophrenia: a double-blind, placebo-controlled trial","volume":"70","author":"Nakamura","year":"2009","journal-title":"J\u00a0Clin Psychiatry"},{"key":"10.1016\/j.psc.2016.01.008_bib185","doi-asserted-by":"crossref","first-page":"1400","DOI":"10.1038\/sj.npp.1300203","article-title":"Aripiprazole, a novel atypical antipsychotic drug with a unique and robust pharmacology","volume":"28","author":"Shapiro","year":"2003","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.psc.2016.01.008_bib186","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1097\/JCP.0b013e318205e1aa","article-title":"Preliminary report: a naturalistic study of the effect of aripiprazole addition on risperidone-related hyperprolactinemia in patients treated with risperidone long-acting injection","volume":"31","author":"Kooten","year":"2011","journal-title":"J\u00a0Clin Psychopharmacol"},{"issue":"5","key":"10.1016\/j.psc.2016.01.008_bib187","first-page":"90","article-title":"Aripiprazole reverses paliperidone-induced hyperprolactinemia","volume":"40","author":"Basterreche","year":"2012","journal-title":"Actas Esp Psiquiatr"},{"key":"10.1016\/j.psc.2016.01.008_bib188","doi-asserted-by":"crossref","first-page":"1404","DOI":"10.1176\/appi.ajp.2007.06071075","article-title":"Adjunctive treatment with a dopamine partial agonist, aripiprazole, for antipsychotic-induced hyperprolactinemia: a placebo-controlled trial","volume":"164","author":"Shim","year":"2007","journal-title":"Am J Psychiatry"},{"key":"10.1016\/j.psc.2016.01.008_bib189","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1177\/0269881107082901","article-title":"Change in sexual dysfunction with aripiprazole: a switching or add-on study","volume":"22","author":"Mir","year":"2008","journal-title":"J\u00a0Psychopharmacol"},{"key":"10.1016\/j.psc.2016.01.008_bib190","doi-asserted-by":"crossref","first-page":"1153","DOI":"10.1016\/j.pnpbp.2010.06.003","article-title":"Using aripiprazole to attenuate paliperidone-induced hyperprolactinemia","volume":"34","author":"Rocha","year":"2010","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"key":"10.1016\/j.psc.2016.01.008_bib191","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1177\/0269881107087373","article-title":"Current guidelines and their recommendations for prolactin monitoring in psychosis","volume":"22","author":"Citrome","year":"2008","journal-title":"J\u00a0Psychopharmacol"},{"issue":"2 Suppl","key":"10.1016\/j.psc.2016.01.008_bib192","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1177\/0269881107087346","article-title":"Antipsychotics and hyperprolactinemia: clinical recommendations","volume":"22","author":"Peveler","year":"2008","journal-title":"J\u00a0Psychopharmacol"},{"issue":"1","key":"10.1016\/j.psc.2016.01.008_bib193","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.psym.2013.08.008","article-title":"Psychotropic-Induced Hyperprolactinemia: a clinical review","volume":"55","author":"Ajmal","year":"2014","journal-title":"Psychosomatics"},{"key":"10.1016\/j.psc.2016.01.008_bib194","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1002\/hup.924","article-title":"Sexual dysfunction in schizophrenia: focus on recent evidence","volume":"23","author":"Baggaley","year":"2008","journal-title":"Hum Psychopharmacol"},{"key":"10.1016\/j.psc.2016.01.008_bib195","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1097\/YIC.0b013e328341e434","article-title":"A\u00a0meta-analysis of sexual dysfunction in psychiatric patients taking antipsychotics","volume":"26","author":"Serretti","year":"2011","journal-title":"Int Clin Psychopharmacol"},{"key":"10.1016\/j.psc.2016.01.008_bib196","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/S0074-7742(08)00008-1","article-title":"Sexual dysfunction in women with epilepsy: role of antiepileptic drugs and psychotropic medications","volume":"83","author":"Gutierrez","year":"2008","journal-title":"Int Rev Neurobiol"},{"key":"10.1016\/j.psc.2016.01.008_bib197","series-title":"Stahl's essential psychopharmacology: Neuroscientific basis and practical applications","first-page":"129","author":"Stahl","year":"2013"},{"key":"10.1016\/j.psc.2016.01.008_bib198","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1055\/s-0033-1347177","article-title":"Sexual dysfunction related to psychotropic drugs: a critical review part II: antipsychotics","volume":"46","author":"Torre","year":"2013","journal-title":"Pharmacopsychiatry"},{"issue":"10","key":"10.1016\/j.psc.2016.01.008_bib199","doi-asserted-by":"crossref","first-page":"830","DOI":"10.3109\/00048674.2011.589044","article-title":"Antipsychotic-induced hyperprolactinemia","volume":"45","author":"Inder","year":"2011","journal-title":"Aust N Z J Psychiatry"},{"issue":"12","key":"10.1016\/j.psc.2016.01.008_bib200","doi-asserted-by":"crossref","first-page":"2259","DOI":"10.1517\/14656566.4.12.2259","article-title":"Sexual dysfunction with psychotropic drugs","volume":"4","author":"Gitlin","year":"2003","journal-title":"Expert Opin Pharmacother"},{"key":"10.1016\/j.psc.2016.01.008_bib201","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1001\/jama.281.6.537","article-title":"Sexual dysfunction in the United States","volume":"281","author":"Laumann","year":"1999","journal-title":"JAMA"},{"key":"10.1016\/j.psc.2016.01.008_bib202","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1192\/bjp.181.1.49","article-title":"Sexual dysfunction in patients taking conventional antipsychotic medication","volume":"181","author":"Smith","year":"2002","journal-title":"Br J Psychol"},{"key":"10.1016\/j.psc.2016.01.008_bib203","doi-asserted-by":"crossref","first-page":"361","DOI":"10.4088\/JCP.v68n0302","article-title":"Sexual function and gonadal hormones in patients taking antipsychotic treatment for schizophrenia or schizoaffective disorder","volume":"68","author":"Howes","year":"2007","journal-title":"J\u00a0Clin Psychiatry"},{"key":"10.1016\/j.psc.2016.01.008_bib204","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/j.psyneuen.2008.02.008","article-title":"Are sexual side effects of prolactin-raising antipsychotics reducible to serum prolactin?","volume":"33","author":"Knegtering","year":"2008","journal-title":"Psychoneuroendocrinology"},{"issue":"5","key":"10.1016\/j.psc.2016.01.008_bib205","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1517\/14740338.2014.906579","article-title":"Second-generation and newly approved antipsychotics, serum prolactin levels and sexual dysfunctions: a critical literature review","volume":"13","author":"De Hert","year":"2014","journal-title":"Expert Opin Drug Saf"},{"issue":"2","key":"10.1016\/j.psc.2016.01.008_bib206","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1080\/0092623X.2011.606883","article-title":"Strategies for the treatment of antipsychotic-induced sexual dysfunction and\/or hyperprolactinemia among patients of the schizophrenia spectrum: a review","volume":"38","author":"Nunes","year":"2012","journal-title":"J\u00a0Sex Marital Ther"},{"issue":"11","key":"10.1016\/j.psc.2016.01.008_bib207","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD003546.pub3","article-title":"Management of sexual dysfunction due to antipsychotic drug therapy","author":"Schmidt","year":"2012","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.psc.2016.01.008_bib208","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1097\/JCP.0b013e3181c8273d","article-title":"Priapism associated with antipsychotics: role of alpha1 adrenoreceptor affinity","volume":"30","author":"Andersohn","year":"2010","journal-title":"J\u00a0Clin Psychopharmacol"},{"key":"10.1016\/j.psc.2016.01.008_bib209","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1097\/01.jcp.0000239792.29449.3c","article-title":"Priapism associated with the switch from oral to injectable risperidone","volume":"26","author":"Kirshner","year":"2006","journal-title":"J\u00a0Clin Psychopharmacol"},{"key":"10.1016\/j.psc.2016.01.008_bib210","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1016\/j.genhosppsych.2014.03.011","article-title":"Priapism associated with iloperidone: a case report","volume":"36","author":"Rodriguez-Cabezas","year":"2014","journal-title":"Gen Hosp Psychiatry"},{"key":"10.1016\/j.psc.2016.01.008_bib211","doi-asserted-by":"crossref","first-page":"167138","DOI":"10.1155\/2013\/167138","article-title":"Osteoporosis associated with antipsychotic treatment in schizophrenia","volume":"2013","author":"Wu","year":"2013","journal-title":"Int J Endocrinol"},{"key":"10.1016\/j.psc.2016.01.008_bib212","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1111\/acps.12313","article-title":"A\u00a0meta-analysis of prevalence estimates and moderators of low bone mass in people with schizophrenia","volume":"130","author":"Stubbs","year":"2014","journal-title":"Acta Psychiatr Scand"},{"key":"10.1016\/j.psc.2016.01.008_bib213","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1097\/YCO.0b013e328355e1ac","article-title":"Osteoporosis and fracture risk in people with schizophrenia","volume":"25","author":"Kishimoto","year":"2012","journal-title":"Curr Opin Psychiatry"},{"key":"10.1016\/j.psc.2016.01.008_bib214","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1002\/hup.1265","article-title":"Is antipsychotic treatment linked to bone mineral density and osteoporosis? A review of the evidence and the clinical implications","volume":"27","author":"Crews","year":"2012","journal-title":"Hum Psychopharmacol"},{"key":"10.1016\/j.psc.2016.01.008_bib215","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1097\/01.jcp.0000150223.31007.e0","article-title":"Antipsychotic drugs: a new risk factor for osteoporosis in young women with schizophrenia?","volume":"25","author":"O\u2019Keane","year":"2005","journal-title":"J\u00a0Clin Psychopharmacol"},{"key":"10.1016\/j.psc.2016.01.008_bib216","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1016\/j.schres.2007.01.013","article-title":"Bone mineral density changes over a years in young females with schizophrenia: relationship to medication and endocrine variables","volume":"93","author":"Meaney","year":"2007","journal-title":"Schizophr Res"},{"issue":"2 suppl","key":"10.1016\/j.psc.2016.01.008_bib217","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1177\/0269881107088439","article-title":"Antipsychotic-induced hyperprolactinemia, hypogonadism and osteoporosis in the treatment of schizophrenia","volume":"22","author":"O\u2019Keane","year":"2008","journal-title":"J\u00a0Psychopharmacol"},{"key":"10.1016\/j.psc.2016.01.008_bib218","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/S0920-9964(01)00321-8","article-title":"Bone mineral desnity and prolactin assocations in patients with chronic schizophrenia","volume":"59","author":"Abraham","year":"2003","journal-title":"Schizophr Res"},{"key":"10.1016\/j.psc.2016.01.008_bib219","doi-asserted-by":"crossref","first-page":"382","DOI":"10.4088\/JCP.v69n0307","article-title":"Antipsychotic-induced hyperprolactinaemia inhibits the hypothalamo-pituitary-gonadal axis and reduces bone mineral desnity in male pateints with schizophrenia","volume":"69","author":"Kishimoto","year":"2008","journal-title":"J\u00a0Clin Psychiatry"},{"key":"10.1016\/j.psc.2016.01.008_bib220","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1097\/01.jcp.0000162798.87249.4d","article-title":"Bone mineral density and its relationship to prolactin levels in patients taking antipsychotic treatment","volume":"25","author":"Howes","year":"2005","journal-title":"J\u00a0Clin Psychopharmacol"},{"key":"10.1016\/j.psc.2016.01.008_bib221","doi-asserted-by":"crossref","first-page":"278","DOI":"10.4306\/pi.2010.7.4.278","article-title":"Bone density in chronic schizophrenia with long-tern antipsychotic treatment: Preliminary study","volume":"7","author":"Lee","year":"2010","journal-title":"Psychiatry Investig"},{"key":"10.1016\/j.psc.2016.01.008_bib222","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1016\/j.genhosppsych.2015.01.004","article-title":"Schizophrenia and the risk of fractures: a systematic review and comparative meta-analysis","volume":"37","author":"Stubbs","year":"2015","journal-title":"Gen Hosp Psychiatry"},{"key":"10.1016\/j.psc.2016.01.008_bib223","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1016\/j.euroneuro.2013.04.002","article-title":"Schizophrenia, antipsychotics and risk of hip fracture: A population-based analysis","volume":"23","author":"Sorenson","year":"2013","journal-title":"Eur Neuropsychopharmacol"},{"key":"10.1016\/j.psc.2016.01.008_bib224","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1345\/aph.1Q589","article-title":"Psychotropic-related hip fractures: Meta-analysis of first-generation and second-generation antidepressant and antipsychotic drugs","volume":"46","author":"Oderda","year":"2012","journal-title":"Ann Pharmacother"}],"container-title":["Psychiatric Clinics of North America"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0193953X16000095?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0193953X16000095?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2023,8,17]],"date-time":"2023-08-17T11:12:09Z","timestamp":1692270729000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0193953X16000095"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,6]]},"references-count":224,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2016,6]]}},"alternative-id":["S0193953X16000095"],"URL":"https:\/\/doi.org\/10.1016\/j.psc.2016.01.008","relation":{},"ISSN":["0193-953X"],"issn-type":[{"value":"0193-953X","type":"print"}],"subject":[],"published":{"date-parts":[[2016,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Detecting and Managing Adverse Effects of Antipsychotic Medications","name":"articletitle","label":"Article Title"},{"value":"Psychiatric Clinics of North America","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.psc.2016.01.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}